Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma based on standard diagnostic criteria or by the new International Myeloma Foundation 2003 Diagnostic Criteria~* Relapsed or relapsed and refractory disease after receiving between 1 and 3 prior regimens~* Negative serum or urine pregnancy test~* Age 18 years or older~* Karnofsky performance status of 60 or greater~Exclusion Criteria:~* Grade 2 or greater peripheral neuropathy within 14 days before enrollment~* Renal insufficiency (serum creatinine \> 2.5 mg/dL)~* Evidence of mucosal or internal bleeding and/or platelet refractory~* ANC \< 1000 cells/mm3~* Hemoglobin \< 8.0 g/dL~* AST or ALT greater than or equal to 2 x ULN~* Concomitant therapy medications that include corticosteroids~* Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Clinically relevant active infection or serious co-morbid medical conditions~* Prior malignancy (within last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or breast cancer, in situ prostate cancer~* Pregnant or breast-feeding~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Uncontrolled diabetes mellitus~* Hypersensitivity to acyclovir or similar anti-viral drug~* POEMS syndrome~* Known HIV infection~* Known active hepatitis B or C viral infection~* Known intolerance to steroid therapy~* Subjects with primary refractory disease, defined as progression during initial treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lenalidomide, dexamethasone, bortezomib combination (Type: EXPERIMENTAL): Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).